From Chromatographic Optimisation to Bioanalysis: HPLC System Comparison and HPLC–QTRAP–MS/MS Determination of Cariprazine and Lurasidone in Human Serum, Urine, and Saliva

Cariprazine (CAR) and lurasidone (LUR) are antipsychotic drugs used to treat schizophrenia. These drugs are relatively new in clinical practice, and there is a need to optimise and develop analytical methods for their determination in various biological matrices for biomedical analysis. To date, the detection of these drugs has been performed in serum and urine, but there are no methods for determining these drugs in saliva. In the first part of this study, various chromatographic systems were compared using high-performance liquid chromatography with diode array detection (HPLC-DAD) or coupled with quadrupole–linear ion trap tandem mass spectrometry (HPLC-QTRAP-MS/MS), taking into account the retention of tested compounds, system efficiency and peak symmetry. Next, a simple, rapid, and sensitive HPLC-QTRAP-MS/MS method has been developed for the determination of CAR and LUR in human serum, urine, and, for the first time, in saliva samples. Solid-phase extraction (SPE) was used for sample pre-treatment. Quantifications were carried out using a Polar RP column with a mobile phase consisting of acetonitrile and a formate buffer at pH 4.0 in gradient mode. The method was successfully applied for the determination of CAR and LUR in biological samples obtained from psychiatric patients. The findings suggest that saliva may be a non-invasive alternative for the quantification of free levels of investigated drugs, although further studies are required to clarify its relationship with plasma concentrations.